HAIFA, ISRAEL, January 4, 2011 --Pluristem Therapeutics Inc. (NasdaqCM: PSTI), today announced that the Tel-Aviv Stock Exchange (“TASE”) has approved the inclusion of the company’s ordinary shares on four TASE equity indexes: Tel-Tech, TA Composite, MidCap TA and Biomed beginning on January 9, 2011.

The shares will be added to the indexes under the "fast track" for adding shares to the Tel Aviv Stock Exchange's indexes.

About Pluristem

Pluristem Therapeutics Inc. (NasdaqCM: PSTI; DAX: PJT) is the world's leading developer of placenta-based cell therapies. The company's patented PLX (PLacental eXpanded) cells drug delivery platform releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory diseases. PLX cells are grown using the company’s proprietary 3D micro-environmental technology and are an off-the-shelf product that requires no tissue matching prior to administration. Data from phase I/IIa studies indicate Pluristem’s first PLX product, PLX-PAD, is potentially safe and effective for the treatment of end stage Peripheral Artery Disease. Pluristem’s pre-clinical animal models have demonstrated PLX cells are also potentially effective in nerve pain and muscle damage when administered locally and in inflammatory bowel disease, MS and stroke when administered systemically.

Pluristem has a strong patent portfolio, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release. Follow Pluristem on Twitter @Pluristem.